12.81
3.47%
-0.46
Assembly Biosciences Inc stock is currently priced at $12.81, with a 24-hour trading volume of 20,698.
It has seen a -3.47% decreased in the last 24 hours and a -5.11% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $13.15 pivot point. If it approaches the $12.46 support level, significant changes may occur.
Previous Close:
$13.27
Open:
$13.28
24h Volume:
20,698
Market Cap:
$70.23M
Revenue:
-
Net Income/Loss:
$-61.23M
P/E Ratio:
-7.8589
EPS:
-1.63
Net Cash Flow:
$22.49M
1W Performance:
-4.12%
1M Performance:
-5.11%
6M Performance:
+1,372%
1Y Performance:
+1,144%
Assembly Biosciences Inc Stock (ASMB) Company Profile
Name
Assembly Biosciences Inc
Sector
Industry
Phone
833 509 4583
Address
331 Oyster Point Boulevard, Fourth Floor, South San Francisco
Assembly Biosciences Inc Stock (ASMB) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-13-21 | Initiated | H.C. Wainwright | Neutral |
Sep-02-21 | Downgrade | William Blair | Outperform → Mkt Perform |
Mar-23-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Nov-06-20 | Downgrade | Jefferies | Buy → Hold |
Oct-19-20 | Initiated | Truist | Buy |
Oct-16-19 | Initiated | Mizuho | Buy |
Nov-19-18 | Initiated | Leerink Partners | Outperform |
Oct-08-18 | Upgrade | B. Riley FBR | Neutral → Buy |
Aug-08-18 | Initiated | Robert W. Baird | Outperform |
Apr-13-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
Jan-05-18 | Initiated | B. Riley FBR, Inc. | Neutral |
Nov-08-17 | Initiated | Jefferies | Buy |
May-30-17 | Initiated | Chardan Capital Markets | Buy |
View All
Assembly Biosciences Inc Stock (ASMB) Latest News
Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year?
Zacks Investment Research
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights
GlobeNewswire Inc.
Why Icosavax Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
Benzinga
Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Assembly Biosciences Inc Stock (ASMB) Financials Data
Assembly Biosciences Inc (ASMB) Net Income 2024
ASMB net income (TTM) was -$61.23 million for the quarter ending December 31, 2023, a +34.23% increase year-over-year.
Assembly Biosciences Inc (ASMB) Cash Flow 2024
ASMB recorded a free cash flow (TTM) of $22.49 million for the quarter ending December 31, 2023, a +126.59% increase year-over-year.
Assembly Biosciences Inc (ASMB) Earnings per Share 2024
ASMB earnings per share (TTM) was -$13.52 for the quarter ending December 31, 2023, a +41.57% growth year-over-year.
About Assembly Biosciences Inc
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Cap:
|
Volume (24h):